Tuesday, November 4, 2025 11/4/2025

AI/ML and iPSC-Derived Organoids for Myotonic Dystrophy Drug Discovery

Award Number: R21TR004938
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

AI/ML and iPSC-Derived Organoids for Myotonic Dystrophy Drug Discovery - PROJECT SUMMARY/ABSTRACT Drug discovery for rare diseases is often limited by the lack of relevant preclinical models that adequately capture the complexity and diversity of patients affected. Furthermore, clinical trials are burdened with challenges in patient recruitment and stratification to assess the safety and efficacy of a drug candidate. The ability to use in vitro cellular data for efficacy assessment will create drug development opportunities for rare diseases that were previously considered too challenging due to the small number of patients. To enable the use of data from relevant cellular models to replace, reduce or refine clinical trials for rare diseases, this proposal will leverage human induced pluripotent stem cells (iPSCs), a well-established tool for patient-specific and disease-specific modeling in vitro, to advance the concept of “clinical trial in a dish” to accelerate, de-risk, and streamline drug discovery for rare diseases. Additionally, we combine iPSC technology with artificial intelligence and machine learning (AI/ML) to discover novel therapeutic compounds that are predicted to have significantly improved safety and efficacy. Here, we leverage our expertise in myotonic dystrophy type 1 (DM1) as a rare disease with unmet needs to apply our iPSC-AI/ML drug discovery platform. DM1 is a monogenic rare disease affecting nearly 1 in 2,100 in the general population and is the most common adult form of muscular dystrophy. It is a progressive multi-systemic disease with cardiovascular complications being the second leading cause of death behind respiratory failure. To date, there is no treatment for the heart in DM1 and no pharmacological treatments available for the prevalent arrhythmias. The main standard of care for DM1 patients at risk of arrhythmias and sudden cardiac death is an implantable cardioverter defibrillator (ICD). Specific Aim 1 will utilize AI/ML to identify safe and novel compounds with high binding affinity to RNA structures formed by expanded CUG repeats in the RNA from the DMPK gene, which is the underlying cause of the disease. Specific Aim 2 will then evaluate these drugs in iPSC-derived cardiac organoids and in DM1 mouse model. The outcome of this project will inform the development of general standards, quality control criteria, and best practices for in vitro models to be used for rare disease safety and efficacy assessment for clinical trial readiness.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $192,500 )
2025	2025	GREENSTONE BIOSCIENCES, INC.	3160 PORTER DR STE 200	PALO ALTO	CA	94304	SANTA CLARA	USA	National Center for Advancing Translational Sciences	001	2	9/26/2025	NON-COMPETING CONTINUATION	$0
2025	2025	GREENSTONE BIOSCIENCES, INC.	3160 PORTER DR STE 200	PALO ALTO	CA	94304	SANTA CLARA	USA	National Center for Advancing Translational Sciences	000	2	7/28/2025	NON-COMPETING CONTINUATION	$192,500
														Subtotal = $192,500

Issue Date FY: 2024 ( Subtotal = $110,000 )
2024	2024	GREENSTONE BIOSCIENCES, INC.	3160 PORTER DR STE 200	PALO ALTO	CA	94304	SANTA CLARA	USA	National Center for Advancing Translational Sciences	000	1	5/30/2024	NEW	$110,000
														Subtotal = $110,000

Grand Total All Awards = $302,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AI/ML and iPSC-Derived Organoids for Myotonic Dystrophy Drug Discovery

Award Number: R21TR004938

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer